FRE — Fresenius SE & Co KGaA Share Price
Last trade - 00:00- €23.99bn
- €34.31bn
- €21.83bn
- 82
- 50
- 97
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.38 | ||
| PEG Ratio (f) | 0.74 | ||
| EPS Growth (f) | 20.08% | ||
| Dividend Yield (f) | 2.6% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 11.11 | ||
| Price to Free Cashflow | 15.44 | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | 11.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.49% | ||
| Return on Equity | 5.55% | ||
| Operating Margin | 8.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 36,277 | 37,520 | 21,532 | 21,067 | 21,833 | 22,714.17 | 23,831.53 | -9.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -5.83 | -21.5 | -11.2 | -8.29 | +17.21 | +29.05 | +12.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fresenius SE & Co KGaA is a Germany-based healthcare company. The Company has operationally managed divisions Fresenius Kabi and Fresenius Helios as well as the holdings Fresenius Vamed and Fresenius Medical Care. Fresenius Kabi offers healthcare products for critically and chronically ill patients and offers essential medicines and medical technology for infusion, transfusion and clinical nutrition and its product portfolio includes intravenously administered generic medicines, infusion therapies and clinical nutrition. Fresenius Helios is a private hospital operator that operates clinics, medical facilities, rehabilitation centers and others. Fresenius Vamed provides services for hospitals and other healthcare facilities such as prevention, construction, service and operational management. Fresenius Medical Care offers products and services along the dialysis value chain and is a supplier of dialysis products such as dialysis machines, dialyzers and associated disposable accessories.
Directors
- Gerd Krick CSU (82)
- Stephan Sturm CMG (58)
- Michael Diekmann VSU (66)
- Grit Genster VSU (48)
- Rachel Empey CFO (44)
- Sebastian Biedenkopf MGB (57)
- Francesco De Meo MGB (58)
- Mats Henriksson MGB (54)
- Rice Powell MGB (66)
- Ernst Wastler MGB (63)
- D. Michael Albrecht IND (71)
- Stefanie Balling IND (52)
- Bernd Behlert IND (62)
- Oscar de Paco IND (47)
- Konrad Koelbl IND (61)
- Frauke Lehmann IND (57)
- Iris Loew-Friedrich IND (60)
- Klaus-Peter Mueller IND (76)
- Hauke Stars IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 28th, 2011
- Public Since
- December 18th, 1986
- No. of Employees
- 175,202
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 563,237,277
- Address
- Else-Kroener-Str. 1, BAD HOMBURG, 61352
- Web
- https://www.fresenius.com/
- Phone
- +49 61726080
- Contact
- Nick Stone
- Auditors
- PricewaterhouseCoopers GmbH
Latest News for FRE
Upcoming Events for FRE
Q2 2025 Fresenius SE & Co KGaA Earnings Release
Q2 2025 Fresenius SE & Co KGaA Earnings Call
Q3 2025 Fresenius SE & Co KGaA Earnings Release
Q3 2025 Fresenius SE & Co KGaA Earnings Call
Similar to FRE
FAQ
As of Today at 20:41 UTC, shares in Fresenius SE & Co KGaA are trading at €42.59. This share price information is delayed by 15 minutes.
Shares in Fresenius SE & Co KGaA last closed at €42.59 and the price had moved by +51.94% over the past 365 days. In terms of relative price strength the Fresenius SE & Co KGaA share price has outperformed the FTSE Global All Cap Index by +43.44% over the past year.
The overall consensus recommendation for Fresenius SE & Co KGaA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Fresenius SE & Co KGaA dividend yield is 2.35% based on the trailing twelve month period.
Last year, Fresenius SE & Co KGaA paid a total dividend of €1.00, and it currently has a trailing dividend yield of 2.35%. We do not have any data on when Fresenius SE & Co KGaA is to next pay dividends.
We do not have data on when Fresenius SE & Co KGaA is to next pay dividends. The historic dividend yield on Fresenius SE & Co KGaA shares is currently 2.35%.
To buy shares in Fresenius SE & Co KGaA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €42.59, shares in Fresenius SE & Co KGaA had a market capitalisation of €23.99bn.
Here are the trading details for Fresenius SE & Co KGaA:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: FRE
Based on an overall assessment of its quality, value and momentum Fresenius SE & Co KGaA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Fresenius SE & Co KGaA is €48.50. That is 13.88% above the last closing price of €42.59.
Analysts covering Fresenius SE & Co KGaA currently have a consensus Earnings Per Share (EPS) forecast of €3.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fresenius SE & Co KGaA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +18.53%.
As of the last closing price of €42.59, shares in Fresenius SE & Co KGaA were trading +14.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Fresenius SE & Co KGaA PE ratio based on its reported earnings over the past 12 months is 12.38. The shares last closed at €42.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Fresenius SE & Co KGaA's management team is headed by:
- Gerd Krick - CSU
- Stephan Sturm - CMG
- Michael Diekmann - VSU
- Grit Genster - VSU
- Rachel Empey - CFO
- Sebastian Biedenkopf - MGB
- Francesco De Meo - MGB
- Mats Henriksson - MGB
- Rice Powell - MGB
- Ernst Wastler - MGB
- D. Michael Albrecht - IND
- Stefanie Balling - IND
- Bernd Behlert - IND
- Oscar de Paco - IND
- Konrad Koelbl - IND
- Frauke Lehmann - IND
- Iris Loew-Friedrich - IND
- Klaus-Peter Mueller - IND
- Hauke Stars - IND